Nuveen
EOLS icon

Nuveen’s Evolus EOLS Stock Holding History

Nuveen’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
233,614
+122,012
+109% +$720K ﹤0.01% 2688
2026
Q1 		$459K Buy
111,602
+23,233
+26% +$113K ﹤0.01% 2872
2025
Q4 		$588K Sell
88,369
-982,998
-92% -$6.66M ﹤0.01% 2813
2025
Q3 		$6.58M Buy
1,071,367
+174,895
+20% +$1.36M ﹤0.01% 1773
2025
Q2 		$8.26M Sell
896,472
-128,465
-13% -$1.31M ﹤0.01% 1626
2025
Q1 		$12.3M Buy
1,024,937
+255,361
+33% +$3.34M ﹤0.01% 1426
2024
Q4 		$8.5M Sell
769,576
-127,530
-14% -$1.79M ﹤0.01% 1682
2024
Q3 		$14.5M Buy
897,106
+301,827
+51% +$4.22M ﹤0.01% 1392
2024
Q2 		$6.46M Sell
595,279
-56,986
-9% -$701K ﹤0.01% 1818
2024
Q1 		$9.13M Sell
652,265
-270,639
-29% -$3.52M ﹤0.01% 1652
2023
Q4 		$9.72M Sell
922,904
-351,265
-28% -$3.14M ﹤0.01% 1600
2023
Q3 		$11.6M Buy
1,274,169
+579,854
+84% +$5.2M ﹤0.01% 1377
2023
Q2 		$5.05M Sell
694,315
-109,143
-14% -$941K ﹤0.01% 1905
2023
Q1 		$6.8M Sell
803,458
-125,933
-14% -$1.14M ﹤0.01% 1718
2022
Q4 		$6.98M Buy
929,391
+26,250
+3% +$203K ﹤0.01% 1722
2022
Q3 		$7.27M Sell
903,141
-123,487
-12% -$1.31M ﹤0.01% 1677
2022
Q2 		$11.9M Buy
1,026,628
+94,021
+10% +$1.11M ﹤0.01% 1398
2022
Q1 		$10.2M Buy
932,607
+15,576
+2% +$133K ﹤0.01% 1627
2021
Q4 		$5.14M Buy
917,031
+106,052
+13% +$728K ﹤0.01% 2094
2021
Q3 		$6.67M Buy
810,979
+209,617
+35% +$2.17M ﹤0.01% 2061
2021
Q2 		$7.61M Buy
601,362
+526,591
+704% +$5.79M ﹤0.01% 2018
2021
Q1 		$971K Sell
74,771
-9,606
-11% -$88.5K ﹤0.01% 2891
2020
Q4 		$284K Sell
84,377
-6,807
-7% -$25.6K ﹤0.01% 3142
2020
Q3 		$356K Buy
91,184
+19,546
+27% +$71.4K ﹤0.01% 3043
2020
Q2 		$379K Sell
71,638
-14,845
-17% -$68.4K ﹤0.01% 2994
2020
Q1 		$359K Buy
86,483
+20,273
+31% +$172K ﹤0.01% 2884
2019
Q4 		$806K Buy
66,210
+1,194
+2% +$16.8K ﹤0.01% 2761
2019
Q3 		$1.02M Buy
65,016
+11,618
+22% +$190K ﹤0.01% 2699
2019
Q2 		$781K Buy
+53,398
New +$1.06M ﹤0.01% 2836

Other funds holding EOLS

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Nuveen's EOLS Position: Q2 2026 in Review

Nuveen increased its Evolus (EOLS) stake by 109% in Q2 2026, buying an estimated $720K and bringing the position to 233,614 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2688.

Nuveen first reported a position in EOLS in Q2 2019 and has held it in 29 quarters since. The position peaked at $14.5M in Q3 2024. 158 funds tracked by Wall St. Rank hold EOLS as of Q2 2026.

  • Nuveen held 233,614 shares of Evolus worth $1.62M as of Q2 2026.
  • Nuveen bought 122,012 Evolus shares in Q2 2026, an estimated $720K.
  • Evolus made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2688 holding.
  • Nuveen first reported a position in Evolus in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Evolus position peaked at $14.5M in Q3 2024.
  • 158 funds tracked by Wall St. Rank held Evolus as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.